Go to content
UR Home

Pharmacogenomics of cholesterol-lowering therapy

Schmitz, Gerd and Langmann, Thomas (2006) Pharmacogenomics of cholesterol-lowering therapy. Vascular pharmacology 44 (2), pp. 75-89.

Full text not available from this repository.

at PubMed

at publisher (via DOI)

Other URL: http://dx.doi.org/10.1016/j.vph.2005.07.012


The prevention of cardiovascular disease is critically dependent on lipid-lowering therapy, including 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), cholesterol absorption inhibitors, bile acid resins, fibrates, and nicotinic acid. Although these drugs are generally well tolerated, severe adverse effects can occur in a minority of patients. Furthermore, a ...


Export bibliographical data

Item type:Article
Date:February 2006
Institutions:Medicine > Lehrstuhl für Klinische Chemie und Laboratoriumsmedizin
Identification Number:
16337220PubMed ID
Keywords:HMG-CoA reductase inhibitors; Pharmacogenomics; Pharmacogenetics; Polymorphisms
Dewey Decimal Classification:600 Technology > 610 Medical sciences Medicine
Refereed:Yes, this version has been refereed
Created at the University of Regensburg:Yes
Item ID:800
Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons